crashbandicootsteamunlocked| Aonong Biotech received a regulatory inquiry letter involving issues such as debt repayment arrangements and use of raised funds.
Log in to Sina Finance APP to search [Xinpi] to view more evaluation levels
Beijing News Shell Financial News (Reporter Yan Xia) On May 17, Aonong Biotech received a report from the Shanghai Stock ExchangecrashbandicootsteamunlockedInformation disclosure regulatory inquiry letter on the company's 2023 annual report.
As of the end of 2023, the balance of Aonong's biomeminal funds is 2crashbandicootsteamunlocked.08 billion yuan, a year-on-year decrease of 71.crashbandicootsteamunlocked.12%crashbandicootsteamunlocked; The balance of short-term borrowings was 3.835 billion yuan, the balance of notes payable and accounts payable was 3.557 billion yuan, the balance of other accounts payable was 1.473 billion yuan, and the balance of non-current liabilities due within one year was 1.872 billion yuan. At the end of the reporting period, the company's current ratio was 0.25, the asset-liability ratio exceeded 100%, and it was insolvent. The audit report shows that there is significant uncertainty about the company's ability to continue as a going concern. At present, the company has started work related to pre-reorganization.
In this regard, the Shanghai Stock Exchange required Aonong Biotech to supplement the disclosure of the current funding arrangements and debt repayment arrangements in conjunction with working capital needs, debt maturity structure, etc., as well as the specific measures it has taken or intends to take to ensure the stability of production and operations and maintain its listing status.
The announcement shows that Aonong Biotech plans to terminate the 15000-sow self-breeding pig farm project (Phase I) and the annual output of 180,000 tons of feed (Phase I) project, and permanently replenish the remaining raised funds of 420 million yuan and interest generated after the period. Working capital.
It is worth noting that the above-mentioned raised funds in the previous period have been used for temporary replenishment. This time, the company plans to directly convert the temporary replenishment funds into permanent supplementary working capital and will no longer be returned to the raised funds account.
In this regard, the Shanghai Stock Exchange required Aonong Biotech to provide additional disclosure of the specific circumstances of using idle raised funds to temporarily replenish working capital, and explain whether there were any disguised changes in the use of raised funds, and whether there were any raised funds that ultimately flowed to controlling shareholders, actual controllers and other related parties.
In addition, Aonong Biotech's pig breeding business, trading business, asset impairment, etc. have also attracted the attention of the Shanghai Stock Exchange, and specific questions have been raised to ask Aonong Biotech to respond.
(Article source: Beijing News)